Financial Personal
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
BEIJING & BOSTON — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into an Exclusive Option
BEIJING & BOSTON -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. (“Radiance”), a biotechnology company specializing in developing next generation Antibody Drug Conjugates. Read More
Related
Share this page
Guest Posts by Easy Branches